Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas.
- Author:
Lei YU
1
;
Song-Tao QI
;
Zhi-Yong LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Age Factors; Brain Neoplasms; genetics; pathology; Genes, p53; Glioma; genetics; pathology; Glutarates; metabolism; Humans; Isocitrate Dehydrogenase; genetics; physiology; Ketoglutaric Acids; metabolism; Middle Aged; Mutation; NADP; metabolism; Neoplasm Grading; Prognosis
- From: Chinese Medical Journal 2010;123(24):3697-3705
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo highlight recent researches which may show promise for histomolecular classification and new treatments for gliomas.
DATA SOURCESAll articles cited in this review were mainly searched from PubMed, which were published in English from 1996 to 2010.
STUDY SELECTIONOriginal articles and critical reviews selected were relevant to the isocitrate dehydrogenase-1/2 mutation in gliomas and other tumors.
RESULTSExtraordinary high rates of somatic mutations in isocitrate dehydrogenase-1/2 occur in the majority of World Health Organization grade II and grade III gliomas as well as grade IV secondary glioblastomas. Isocitrate dehydrogenase-1/2 mutations are associated with younger age at diagnosis and a better prognosis in patients with mutated tumors. The functional role of isocitrate dehydrogenase-1/2 mutations in the pathogenesis of gliomas is still unclear.
CONCLUSIONIsocitrate dehydrogenase-1/2 mutations define a specific subtype of gliomas and may have great significance in the diagnosis, prognosis, and treatment of patients with these tumors.
